Navigation Links
UofL research holds promise of therapeutic approach for gum disease
Date:3/27/2012

University of Louisville researchers are a step closer to eliminating periodontal disease through their work to develop synthetic molecules that prevent a bacteria responsible for the disease from spreading throughout the mouth.

The discovery could lead to the formulation of a mouth rinse, toothpaste or tooth varnish to prevent the pathogen from establishing itself orally.

Donald Demuth, PhD, associate dean for research and enterprise, UofL School of Dentistry, received a patent today for his work to develop peptides that inhibit the interaction between P. gingivalis and Streptococcus gordonii and prevent P. gingivalis colonization of the mouth. Peptides are molecules formed when two or more amino acids join together; they are the building blocks of proteins in a cell.

"When P. gingivalis enters the oral environment, it seeks out interaction with the bacterium S. gordonii an otherwise benign organism in order to lay the ground work to propagate and ultimately gain a foothold below the gum line, leading to periodontal disease.

"UofL Oral Health and Systemic Disease Group director Richard Lamont characterized this bacterial interaction and based on those studies, my team developed a series of peptides that prevent P. gingivalis and S. gordonii from coming together," Demuth said.

Demuth found that administering the peptide in an animal model prevented P. gingivalis related bone loss the clinical symptom of periodontal disease -- and prevented the spread of the bacterium in the mouth.

"This is one of the first examples of a potential targeted therapeutic approach that may control periodontal disease," he said.

Demuth is building his research through collaboration with Frederick Luzzio, PhD, professor, UofL College of Arts & Sciences, Department of Chemistry. They hope to further develop organic molecule structures that mimic the active peptides.

"The molecules must be potent and cost effective to manufacture. We know of no chemical technology on the market that targets specific oral pathogens, and this is an exciting endeavor," Luzzio said.

Luzzio and Demuth have a patent pending on certain discoveries related to this research. The investigators are working with the Office of Technology Transfer at UofL to find an industrial partner to license and commercialize the technology.


'/>"/>
Contact: Julie Heflin
julie.heflin@louisville.edu
502-852-7987
University of Louisville
Source:Eurekalert

Related biology news :

1. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
2. Researchers unravel genetic mechanism of fatty liver disease in obese children
3. UC research: Saving habitat key to songbirds survival
4. Montreal researchers repel mortality in Malian mothers
5. UF researchers look for ways to make an emerging technology safe for environment
6. Brandeis scientists win prestigious prize for circadian rhythms research
7. UCSB researchers to examine the effects of year-old NOAA West Coast Catch Shares program
8. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
9. SDSCs big data expertise aiding genomics research
10. Young researcher taking fight against global killer to the next level in Vietnam
11. Space research institute honors Sen. Hutchison with Pioneer Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering ... need to give mom an experience she won’t forget. , Guests that visit ...
(Date:5/4/2016)... ... ... Proove Biosciences, Inc. , the commercial and research leader in personalized pain ... partnership is designed to advance research in pain genetics in an effort to bring ... new agreement, researchers at Proove Biosciences are able to collaborate with Luda Diatechnko, MD, ...
(Date:5/4/2016)... , May 4, 2016  Bayer today ... oncology compound Stivarga ® (regorafenib) tablets for ... (HCC) has met its primary endpoint of a ... called RESORCE, evaluated the efficacy and safety of ... progressed after treatment with sorafenib. The safety and ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, 2016 , ... ... neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the ... treatment or cure. , Through numerous community events held during the month of May, ...
Breaking Biology Technology: